Aldeyra Therapeutics Wraps Up Phase 3 Trial Enrollment For Reproxalap In Dry Eye Disease
Portfolio Pulse from Benzinga Newsdesk
Aldeyra Therapeutics has completed enrollment for its Phase 3 trial of Reproxalap, a treatment for dry eye disease. The company expects to release clinical trial results and potentially resubmit a New Drug Application in the second half of 2024.
June 13, 2024 | 11:04 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aldeyra Therapeutics has completed enrollment for its Phase 3 trial of Reproxalap, a treatment for dry eye disease. The company expects to release clinical trial results and potentially resubmit a New Drug Application in the second half of 2024.
The completion of Phase 3 trial enrollment is a significant milestone for Aldeyra Therapeutics. Positive trial results and a potential NDA resubmission could lead to regulatory approval and commercialization, positively impacting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100